![](https://ml-eu.globenewswire.com/media/81292fcc-6b3a-4e4a-a083-ea4191bf920a/small/ipsen-notified-website-1200x628pix-500kb-max-jpg.jpg)
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-...
Exclusive global rights secured for development, manufacture and commercialization of FS001, completing final stages of pre-clinical development with first-in-class potential FS001 targets a novel tumor associated antigen, highly expressed across a range …